Randomised controlled trial of efficacy of albendazole in intra-abdominal hydatid disease

RETRACTED: Management of liver hydatid cysts – Current perspectives

“…They showed that treatment produced a clear effect on viability and infectivity for mice, which was greater with the longer course of treatment. 31 Absorption of albendazole in humans is very variable and limited to between 5% and 20%. Absorption is mostly from the small intestine, and is metabolized first to albendazole sulphoxide, an active antihelminthic in its own right, and then to the relatively inactive sulphone.…”

Spinal hydatid disease

“…13 Pharmacotherapy Drug therapy with benzimidazole derivatives is proven to be eective in abdominal disease. 8 A course of Albendazole (800 mg daily in two divided doses) is continued for 1 to 6 months (usually 3 months). Albendazole is preferred over Mebendazole due to better pharmacokinetic properties and superior ecacy against helminths.…”

Hydatid Disease: Current Status and Recent Advances

“…Imidazoles are hepatotoxic, can cause neutropenia, thrombocytopenia, alopecia and are potentially embryotoxic and teratogenic. 11,[36][37][38][39][40][41] Recently, percutaneous drainage of hepatic hydatid cysts, popularly known in Europe as the PAIR (Puncture, Aspiration, Installation of scolicidal agent and Reaspiration) technique has gained acceptance. [42][43][44][45][46][47][48] The procedure is minimally invasive, cost-effective, involves reduced hospital stay and has less morbidity and mortality than surgery.…”